2022 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.
Research in Action Awards 2022
Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually to ensure this year’s event is safe and open for participation to our allies and friends across the U.S. and world.
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
Roundtable on Access to Multi-disease Molecular Diagnostics
On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…
Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement
In response to this morning's announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group's Executive Director, Mark Harrington, and TAG HIV Project Director Riko A. Boone, MSW, MPH, MA, said:
2021 Annual Report
This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.
Treatment Action Group Mourns Urvashi Vaid, Celebrates Her Life and Legacy
Treatment Action Group (TAG) today mourns the premature loss of transformative LGBTQ and AIDS activist Urvashi Vaid, formerly executive director of the National Gay and Lesbian Task Force (now the National LGBTQ Task Force) at the height of the U.S. AIDS crisis in the late 1980s and early 1990s, and peerless leader of the LBGTQ movement for many years thereafter.
U.S. Government Funded Research Brings Shorter Tuberculosis Treatment Regimens to New York City
We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB).
From Evidence to Action: Community-led Monitoring for Access to TB Screening and Diagnostic Testing
Treatment Action Group (TAG) and the Coalition of Women Living with HIV and AIDS (COWLHA) hosted this webinar on how community-led monitoring (CLM) can be used to assess, document, and improve the availability, accessibility, acceptability, and quality of local TB screening and diagnostic services.